drugset / Trial / NCT02215018

Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers

NCT02215018

Phase 1 Completed 56 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety, tolerability and pharmacokinetics of single rising oral doses of BI 44370 TA in healthy male volunteers, to compare a drinking solution vs. a tablet formulation and to assess intra-individual pharmacokinetic (PK) variability by re-dosing two further doses.

Timeline

Start
2007-04
Primary completion
2007-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 44370 Small molecule Oral

Indications

No indication recorded.